NCT05279924

Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

Impact of Implementation of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
• Sex: Male
• Age: 2 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast

Detailed description

Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast. Duration of the study: 1 year after initiation of prophylaxis with Emicizumab Inclusion criteria: boys aged \> 2 years, affected with severe hemophilia A with or without inhibitors Evaluated outcomes: annual bleeding rate, days of absence from school, the need for additional facteur VIII consumption, satisfaction about the treatment and quality of life. Tools used to assess quality of life are the Ivoirian version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool version 2 (CHO-KLAT) and EQ-5D The satisfaction of the parents will be assessed using the patients' global impression of change scale (PGIC).

Conditions

• Hemophilia A

Interventions

Type	Name	Description
DRUG	Prophylaxis with Emicizumab	Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A

Timeline

• Start date: 2021-07-01
• Primary completion: 2022-10-20
• Completion: 2022-10-20
• First posted: 2022-03-15
• Last updated: 2022-10-26

Locations

1 site across 1 country: Côte d’Ivoire